Combination therapy for first-line treatment of aggressive B-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of three targeted drugs (tafasitamab, polatuzumab vedotin, and glofitamab) as a first treatment for diffuse large B-cell lymphoma or high-grade B-cell lymphoma. It aims to see if this approach can be effective without standard chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have a confirmed diagnosis of diffuse large B-cell lymphoma or high-grade B-cell lymphoma (specific subtypes are allowed).
- You must not have received previous systemic therapy for your lymphoma, except for corticosteroids, one cycle of emergency chemotherapy, radiation, or prior treatment for a slow-growing lymphoma.
- Your cancer must show activity on a PET-CT scan.
- You must be in generally good health (ECOG performance status 0, 1, or 2) and have adequate blood counts and organ function.
- Women must not be pregnant or nursing, and both men and women must agree to use effective contraception during and for 3 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted therapies, polatuzumab vedotin and glofitamab, for people with DLBCL that either came back within 12 months of R-CHOP or never went away. The goal is to see if this two-drug approach can help when standard chemotherapy has not worked well.
This trial tests a combination of three targeted drugs (glofitamab, polatuzumab vedotin, and zanubrutinib) as a first treatment for older adults (70+) with a common type of lymphoma called DLBCL. The goal is to see if this approach is effective and well-tolerated without standard chemotherapy.
This Phase 2 study tests two medicines—glofitamab and polatuzumab—together with chemotherapy to treat newly diagnosed, high-risk diffuse large B-cell lymphoma (DLBCL) that has the CD20 marker. It aims to improve how well the lymphoma responds and how long responses last.
This trial tests whether combining a short course of radiation with a targeted antibody drug (glofitamab) can help people with aggressive large B-cell lymphoma that came back after treatment, especially if they have bulky tumors. It aims to find a new option for hard-to-treat cases.
This trial tests a combination of three drugs (mosunetuzumab, polatuzumab vedotin, and lenalidomide) for people with diffuse large B-cell lymphoma (a type of blood cancer) that has come back or not responded to previous treatment. The goal is to see if this combination is safe and effective.
This trial tests a combination of targeted antibody drugs (polatuzumab vedotin and rituximab) plus two chemo drugs (gemcitabine and oxaliplatin) for people with DLBCL whose cancer returned after their first treatment and who cannot have a stem cell transplant. The goal is to see if this combination works better as a second-line treatment.
Hear when a new Diffuse Large B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.